Anti-angiogenesis therapy and gap junction inhibition reduce MDA-MB-231 breast cancer cell invasion and metastasis in vitro and in vivo

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Zibara, Kazem ^a   Awada, Zahraa ^a   Dib, Leila ^b   El Saghir, Jamal ^b   Al Ghadban, Sara ^b   Ibrik, Aida ^a   El Zein, Nabil ^a   El Sabban, Marwan ^b  

^a LEBANESE UNIVERSITY   (Lebanon)

^b AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; CHEMOKINE RECEPTOR CXCR4; CONNEXIN 26; CONNEXIN 43; CXCR4 PROTEIN, HUMAN; DFNA3 PROTEIN, HUMAN; GAP JUNCTION PROTEIN; GELATINASE B; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MMP9 PROTEIN, HUMAN; VASCULOTROPIN A;

ANIMAL; BREAST NEOPLASMS; CELL MOTION; CELL PROLIFERATION; DRUG EFFECTS; ENDOTHELIUM CELL; FEMALE; GAP JUNCTION; HUMAN; METABOLISM; MOUSE; NEOVASCULARIZATION, PATHOLOGIC; PREVENTION AND CONTROL; TUMOR CELL LINE; TUMOR INVASION;

ANGIOGENESIS INHIBITORS; ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CONNEXIN 26; CONNEXIN 43; CONNEXINS; ENDOTHELIAL CELLS; FEMALE; GAP JUNCTIONS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MATRIX METALLOPROTEINASE 9; MICE; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, CXCR4; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84938223359     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep12598     Document Type: Article

References (51)

1. Geiger, T. R. & Peeper, D. S. Metastasis mechanisms. Biochim. Biophys. Acta 1796, 293-308 (2009).
2. Woodhouse, E. C., Chuaqui, R. F. & Liotta, L. A. General mechanisms of metastasis. Cancer 80, 1529-1537 (1997).
3. Lorusso, G. & Rüegg, C. The tumor microenvironment and its contribution to tumor evolution toward metastasis. Histochem. Cell Biol. 130, 1091-1103 (2008).
4. Alison, M. R., Lim, S. & Houghton, J. M. Bone marrow-derived cells and epithelial tumours: more than just an inflammatory relationship. Curr. Opin. Oncol. 21, 77-82 (2009).
5. De Maio, A., Vega, V. L. & Contreras, J. E. Gap junctions, homeostasis, and injury. J. Cell Physiol. 191, 269-282 (2002).
6. El-Sabban, M. E. et al. Human T-cell lymphotropic virus type 1-transformed cells induce angiogenesis and establish functional gap junctions with endothelial cells. Blood 99, 3383-3389 (2002).
7. Bazarbachi, A. et al. Human T-cell lymphotropic virus type I-infected cells extravasate through the endothelial barrier by a local angiogenesis-like mechanism. Cancer Res. 64, 2039-2046 (2004).
8. Qin, H. et al. Retroviral delivery of connexin genes to human breast tumor cells inhibits in vivo tumor growth by a mechanism that is independent of significant gap junctional intercellular communication. J. Biol. Chem. 277, 29132-29138 (2002).
9. McLachlan, E., Shao, Q., Wang, H. L., Langlois, S. & Laird, D. W. Connexins act as tumor suppressors in three-dimensional mammary cell organoids by regulating differentiation and angiogenesis. Cancer Res. 66, 9886-9894 (2006).
10. Ohba, Y. et al. Oleamide derivatives suppress the spontaneous metastasis by inhibiting connexin 26. Int. J. Cancer 121, 47-54 (2007).
11. Emlet, D. R. et al. Response to trastuzumab, erlotinib, and bevacizumab, alone and in combination, is correlated with the level of human epidermal growth factor receptor-2 expression in human breast cancer cell lines. Mol. Cancer Ther. 6, 2664-2674 (2007).
12. Tomayko, M. M. & Reynolds, C. P. Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother. Pharmacol. 24, 148-154 (1989).
13. Leber, M. F. & Efferth, T. Molecular principles of cancer invasion and metastasis. Int. J. Oncol. 34, 881-895 (2009).
14. Chung, H. W. & Lim, J. B. Role of the tumor microenvironment in the pathogenesis of gastric carcinoma. World J. Gastroenterol. 20, 1667-1680 (2014).
15. Olechnowicz, S. W. & Edwards, C. M. Contributions of the host microenvironment to cancer-induced bone disease. Cancer Res. 74, 1625-1631 (2014).
16. Saaristo, A., Karpanen, T. & Alitalo, K. Mechanisms of angiogenesis and their use in the inhibition of tumor growth and metastasis. Oncogene 19, 6122-6129 (2000).
17. Greenberg, S. & Rugo, H. S. Triple-negative breast cancer: role of antiangiogenic agents. Cancer J. 16, 33-38 (2010).
18. Chouaib, S. et al. Endothelial cells as key determinants of the tumor microenvironment: interaction with tumor cells, extracellular matrix and immune killer cells. Crit. Rev. Immunol. 30, 529-545 (2010).
19. Reymond, N., d'Água, B. B. & Ridley, A. J. Crossing the endothelial barrier during metastasis. Nat. Rev. Cancer 13, 858-870 (2013).
20. Chen, M. B., Whisler, J. A., Jeon, J. S. & Kamm, R. D. Mechanisms of tumor cell extravasation in an in vitro microvascular network platform. Integr. Biol. 10, 1262-1271 (2013).
21. Iiizumi, M., Mohinta, S., Bandyopadhyay, S. & Watabe, K. Tumor-endothelial cell interactions: therapeutic potential. Microvasc. Res. 74, 114-120 (2007).
22. Goldfarb, S. B., Hudis, C. & Dickler, M. N. Bevacizumab in Metastatic Breast Cancer: when may it be used? Ther. Adv. Med. Oncol. 3, 85-93 (2011).
23. Lerner, R. A. A hypothesis about the endogenous analogue of general anesthesia. Proc. Natl. Acad. Sci. USA 94, 13375-13377 (1997).
24. Krutovskikh, V. A., Piccoli, C. & Yamasaki, H. Gap junction intercellular communication propagates cell death in cancerous cells. Oncogene 21, 1989-1999 (2002).
25. Boger, D. L. et al. Chemical requirements for inhibition of gap junction communication by the biologically active lipid oleamide. Proc. Natl. Acad. Sci. USA 95, 4810-4815 (1998).
26. Rawanduzy, A., Hansen, A., Hansen, T. W. & Nedergaard, M. Effective reduction of infarct volume by gap junction blockade in a rodent model of stroke. J Neurosurg. 87, 916-920 (1997).
27. Huang, G. Y. et al. Gap junction-mediated cell-cell communication modulates mouse neural crest migration. J Cell Biol. 143, 1725-1734 (1998).
28. Véliz, L. P., González, F. G., Duling, B. R., Sáez, J. C. & Boric, M. P. Functional role of gap junctions in cytokine-induced leukocyte adhesion to endothelium in vivo. Am J Physiol Heart Circ Physiol. 295, H1056-H1066 (2008).
29. Videira, P. A. et al. Effects of Bevacizumab on Autocrine VEGF Stimulation in Bladder Cancer Cell Lines. Urol. Int. 86, 95-101 (2011).
30. Chen, S. C., Pelletier, D. B., Ao, P. & Boynton, A. L. Connexin43 reverses the phenotype of transformed cells and alters their expression of cyclin/cyclin-dependent kinases. Cell Growth Differ. 6, 681-690 (1995).
31. Ogawa, K. et al. Silencing of connexin 43 suppresses invasion, migration and lung metastasis of rat hepatocellular carcinoma cells. Cancer Sci. 103, 860-867 (2012).
32. Gerber, H. P. & Ferrara, N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res. 65, 671-680 (2005).
33. Weis, S. M. & Cheresh, D. A. Tumor angiogenesis: molecular pathways and therapeutic targets. Nat. Med. 17, 1359-1370 (2011).
34. Tonini, T., Rossi, F. & Claudio, P. P. Molecular basis of angiogenesis and cancer. Oncogene 22, 6549-6556 (2003).
35. Lee, Y. J. et al. Differential effects of VEGFR-1 and VEGFR2 inhibition on tumor metastases based on host organ environment. Cancer Res. 21, 8357-8367 (2010).
36. Laios, A. et al. Pre-Treatment of Platinum Resistant Ovarian Cancer Cells with an MMP-9/MMP-2 Inhibitor Prior to Cisplatin Enhances Cytotoxicity as Determined by High Content Screening. Int. J. Mol. Sci. 14, 2085-2103 (2013).
37. Rao, J. S. Molecular mechanisms of Glioma invasiveness: the role of proteases. Nat. Rev. Cancer 3, 489-501 (2003).
38. Li, J. K. et al. Inhibition of CXCR4 activity with AMD3100 decreases invasion of human colorectal cancer cells in vitro. World J. Gastroenterol. 14, 2308-2313 (2008).
39. Woenne, E. C. et al. MMP Inhibition Blocks Fibroblast-dependent Skin Cancer Invasion, Reduces Vascularization and Alters VEGF-A and PDGF-BB Expression. Anticancer Res. 30, 703-711 (2010).
40. El-Sabban, M. E. & Pauli, B. U. Cytoplasmic dye transfer between metastatic tumor cells and vascular endothelium. J Cell Biol. 115, 1375-1382 (1991).
41. Hirschi, K. K., Xu, C. E., Tsukamoto, T. & Sager, R. Gap junction genes Cx26 and Cx43 individually suppress the cancer phenotype of human mammary carcinoma cells and restore differentiation potential. Cell Growth Differ. 7, 861-70 (1996).
42. El-Sabban, M. E. et al. ECM-induced gap junctional communication enhances mammary epithelial cell differentiation. J Cell Sci. 116, 3531-3541 (2003).
43. El-Sabban, M. E., Abi-Mosleh, L. F. & Talhouk, R. S. Developmental regulation of gap junctions and their role in mammary epithelial cell differentiation. J Mammary Gland Biol Neoplasia. 8, 463-473 (2003).
44. Laird, D. W. The gap junction proteome and its relationship to disease. Trends Cell Biol. 20, 92-101 (2010).
45. Kapoor, P. et al. Breast cancer metastatic potential: correlation with increased heterotypic gap junctional intercellular communication between breast cancer cells and osteoblastic cells. Int J Cancer. 111, 693-697 (2004).
46. Ito, A. et al. A role for heterologous gap junctions between melanoma and endothelial cells in metastasis. J Clin Invest. 105, 1189-1197 (2000).
47. Kamibayashi, Y., Oyamada, Y., Mori, M. & Oyamada, M. Aberrant expression of gap junction proteins (connexins) is associated with tumor progression during multistage mouse skin carcinogenesis in vivo. Carcinogenesis. 16, 1287-97 (1995).
48. Czyz, J. The stage-specific function of gap junctions during tumourigenesis. Cell Mol Biol Lett. 13, 92-102 (2008).
49. Sun, L., Ma, J. T., Zhang, S. L., Zou, H. W. & Han, C. B. Efficacy and safety of chemotherapy or tyrosine kinase inhibitors combined with bevacizumab versus chemotherapy or tyrosine kinase inhibitors alone in the treatment of non-small cell lung cancer: a systematic review and meta-analysis. Med Oncol. 32, 473 (2015).
50. Poulsen, H. S. et al. The impact of bevacizumab treatment on survival and quality of life in newly diagnosed glioblastoma patients. Cancer Manag Res. 6, 373-87 (2014).
51. Abdel-Rahman, O. & Fouad, M. Bevacizumab-based combination therapy for advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a systematic review of the literature. J Cancer Res Clin Oncol. 141, 295-305 (2015).